Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(50.0%)
Phase 2
3(50.0%)
6Total
Phase 3(3)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02040194Phase 3Completed

AM-101 in the Treatment of Acute Tinnitus 3

Role: lead

NCT03908567Phase 2Completed

AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery

Role: lead

NCT02561091Phase 3Completed

AM-111 in the Treatment of Acute Inner Ear Hearing Loss

Role: lead

NCT02040207Phase 3Completed

AM-101 in the Treatment of Post-Acute Tinnitus 2

Role: lead

NCT00802425Phase 2Completed

Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss

Role: lead

NCT00860808Phase 2Completed

Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus

Role: lead

All 6 trials loaded